U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H28N2O3.C4H4O4
Molecular Weight 508.5629
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of INDACATEROL FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4

InChI

InChIKey=IREJFXIHXRZFER-XRQUGHPZSA-N
InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1+/t22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C24H28N2O3
Molecular Weight 392.4907
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

Originator

Curator's Comment: # Novartis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
76.0 nM [Ki]
91.4 nM [Ki]
76.0 nM [Ki]
91.4 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ARCAPTA NEOHALER

Approved Use

UTIBRONTM NEOHALER® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use: UTIBRON NEOHALER is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.2)

Launch Date

2011
Primary
ARCAPTA

Approved Use

INDICATIONS AND USAGE. ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important limitations: ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ARCAPTA NEOHALER is NOT indicated for asthma.

Launch Date

2011
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.206 ng/mL
150 μg single, respiratory
dose: 150 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.518 ng/mL
300 μg single, respiratory
dose: 300 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.299 ng/mL
150 μg 1 times / day steady-state, respiratory
dose: 150 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.697 ng/mL
300 μg 1 times / day steady-state, respiratory
dose: 300 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
339 pg/mL
110 μg single, respiratory
dose: 110 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered: GLYCOPYRROLATE
INDACATEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
528 pg/mL
110 μg 1 times / day steady-state, respiratory
dose: 110 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: GLYCOPYRROLATE
INDACATEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.974 ng × h/mL
150 μg single, respiratory
dose: 150 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.43 ng × h/mL
300 μg single, respiratory
dose: 300 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.51 ng × h/mL
150 μg 1 times / day steady-state, respiratory
dose: 150 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.52 ng × h/mL
300 μg 1 times / day steady-state, respiratory
dose: 300 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
907 pg × h/mL
110 μg single, respiratory
dose: 110 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered: GLYCOPYRROLATE
INDACATEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2750 pg × h/mL
110 μg 1 times / day steady-state, respiratory
dose: 110 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: GLYCOPYRROLATE
INDACATEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
116 h
150 μg 1 times / day steady-state, respiratory
dose: 150 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
118 h
300 μg 1 times / day steady-state, respiratory
dose: 300 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
INDACATEROL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 ug 1 times / day multiple, respiratory
Highest studied dose
Dose: 800 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 800 ug, 1 times / day
Sources:
unhealthy, 43.5 years (range: 12.0–64.0 years)
Health Status: unhealthy
Age Group: 43.5 years (range: 12.0–64.0 years)
Sex: M+F
Sources:
Disc. AE: Dyspnea, Wheezing...
AEs leading to
discontinuation/dose reduction:
Dyspnea (serious, 1 patient)
Wheezing (serious, 1 patient)
Asthma (moderate, 1 patient)
Cough (moderate, 1 patient)
Sources:
75 ug 1 times / day multiple, respiratory
Dose: 75 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 75 ug, 1 times / day
Sources:
unhealthy
Other AEs: Adverse event...
AEs

AEs

AESignificanceDosePopulation
Asthma moderate, 1 patient
Disc. AE
800 ug 1 times / day multiple, respiratory
Highest studied dose
Dose: 800 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 800 ug, 1 times / day
Sources:
unhealthy, 43.5 years (range: 12.0–64.0 years)
Health Status: unhealthy
Age Group: 43.5 years (range: 12.0–64.0 years)
Sex: M+F
Sources:
Cough moderate, 1 patient
Disc. AE
800 ug 1 times / day multiple, respiratory
Highest studied dose
Dose: 800 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 800 ug, 1 times / day
Sources:
unhealthy, 43.5 years (range: 12.0–64.0 years)
Health Status: unhealthy
Age Group: 43.5 years (range: 12.0–64.0 years)
Sex: M+F
Sources:
Dyspnea serious, 1 patient
Disc. AE
800 ug 1 times / day multiple, respiratory
Highest studied dose
Dose: 800 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 800 ug, 1 times / day
Sources:
unhealthy, 43.5 years (range: 12.0–64.0 years)
Health Status: unhealthy
Age Group: 43.5 years (range: 12.0–64.0 years)
Sex: M+F
Sources:
Wheezing serious, 1 patient
Disc. AE
800 ug 1 times / day multiple, respiratory
Highest studied dose
Dose: 800 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 800 ug, 1 times / day
Sources:
unhealthy, 43.5 years (range: 12.0–64.0 years)
Health Status: unhealthy
Age Group: 43.5 years (range: 12.0–64.0 years)
Sex: M+F
Sources:
Adverse event grade 5
75 ug 1 times / day multiple, respiratory
Dose: 75 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 75 ug, 1 times / day
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
negligible
negligible
no
no
no
unlikely
unlikely
unlikely
unlikely
weak [IC50 10 uM]
weak [IC50 25 uM]
weak [IC50 25 uM]
weak [IC50 5 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
low
low
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
yes (co-administration study)
Comment: Co-administration of indacaterol with verapamil (P-gp inhibitor) showed 2­ fold increase in indacaterol AUC0-24, and 1.5-fold increase in indacaterol Cmax;
Page: 96.0
yes
weak (pharmacogenomic study)
Comment: Nonsignificant trends toward higher Cmax and AUC0-24 (19% and 20%, respectively) were noted in patients with the (TA)7 genotype
Page: 91.0
yes
yes (co-administration study)
Comment: Co-administration of indacaterol with erythromycin (CYP3A4 inhibitor) showed a 1.4-fold increase in indacaterol AUC0-24, and 1.2-fold increase in indacaterol Cmax; Co-administration of indacaterol with ketoconazole caused a 1.9-fold increase in indacaterol AUC0-24, and 1.3-fold increase in indacaterol Cmax; Co-administration of indacaterol with ritonavir resulted in a 1.7-fold increase in indacaterol AUC0-24 whereas indacaterol Cmax was unaffected.
Page: 91.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease.
2005 Jul
Gateways to clinical trials.
2006 Dec
Gateways to clinical trials.
2006 May
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
2007
Gateways to clinical trials.
2007 Dec
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
2007 Dec
Gateways to clinical trials.
2007 Jan-Feb
Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.
2007 Mar
Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study.
2007 Oct
Gateways to clinical trials.
2008 Jan-Feb
Gateways to clinical trials.
2009 Apr
Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?
2009 Dec 8
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
2009 Jul
Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.
2009 Mar 12
Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma.
2009 May
Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.
2009 Sep
Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
2010 Aug
Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
2010 Dec
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
2010 Jun
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
2010 Jun
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist.
2010 Jun 15
Indacaterol for chronic obstructive pulmonary disease (COPD).
2010 Mar
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
2010 Mar 8
Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol.
2010 Nov
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.
2010 Nov
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.
2010 Oct 29
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
2010 Sep
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
2017 Jan 11
Patents

Sample Use Guides

The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.
Route of Administration: Respiratory
In the isolated tracheal strip preparation, indacaterol, demonstrated concentration-dependent inhibition of electrically induced contraction (EC50= 45 ± 13 nM)
Substance Class Chemical
Created
by admin
on Wed Apr 02 01:22:33 GMT 2025
Edited
by admin
on Wed Apr 02 01:22:33 GMT 2025
Record UNII
J3BI9P40XE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDACATEROL FUMARATE
Common Name English
2(1H)-QUINOLINONE, 5-((1R)-2-((5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-HYDROXYETHYL)-8-HYDROXY-, (2E)-2-BUTENEDIOATE (1:1)
Preferred Name English
Code System Code Type Description
PUBCHEM
10255695
Created by admin on Wed Apr 02 01:22:33 GMT 2025 , Edited by admin on Wed Apr 02 01:22:33 GMT 2025
PRIMARY
SMS_ID
100000183718
Created by admin on Wed Apr 02 01:22:33 GMT 2025 , Edited by admin on Wed Apr 02 01:22:33 GMT 2025
PRIMARY
CAS
1000160-87-1
Created by admin on Wed Apr 02 01:22:33 GMT 2025 , Edited by admin on Wed Apr 02 01:22:33 GMT 2025
PRIMARY
FDA UNII
J3BI9P40XE
Created by admin on Wed Apr 02 01:22:33 GMT 2025 , Edited by admin on Wed Apr 02 01:22:33 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY